Ironvine Capital Partners LLC acquired a new stake in Eli Lilly and Co (NYSE:LLY) in the fourth quarter, Holdings Channel reports. The fund acquired 4,725 shares of the company’s stock, valued at approximately $399,000.
Other hedge funds and other institutional investors have also bought and sold shares of the company. BT Investment Management Ltd acquired a new position in shares of Eli Lilly and in the 2nd quarter valued at approximately $2,917,000. Profund Advisors LLC increased its position in Eli Lilly and by 1.5% during the 2nd quarter. Profund Advisors LLC now owns 59,963 shares of the company’s stock worth $4,935,000 after purchasing an additional 859 shares in the last quarter. Westfield Capital Management Co. LP acquired a new position in Eli Lilly and during the 2nd quarter worth approximately $109,309,000. Sandy Spring Bank increased its position in Eli Lilly and by 15.4% during the 2nd quarter. Sandy Spring Bank now owns 2,537 shares of the company’s stock worth $209,000 after purchasing an additional 339 shares in the last quarter. Finally, Thrivent Financial For Lutherans increased its position in Eli Lilly and by 4.4% during the 2nd quarter. Thrivent Financial For Lutherans now owns 39,070 shares of the company’s stock worth $3,215,000 after purchasing an additional 1,654 shares in the last quarter. 76.79% of the stock is owned by hedge funds and other institutional investors.
Shares of Eli Lilly and Co (LLY) opened at $79.61 on Friday. Eli Lilly and Co has a 1-year low of $73.69 and a 1-year high of $89.09. The company has a current ratio of 1.32, a quick ratio of 1.01 and a debt-to-equity ratio of 0.85. The firm has a market cap of $86,431.72, a P/E ratio of -398.03, a price-to-earnings-growth ratio of 1.47 and a beta of 0.28.
The company also recently disclosed a quarterly dividend, which was paid on Friday, March 9th. Stockholders of record on Thursday, February 15th were paid a $0.5625 dividend. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.52. This represents a $2.25 dividend on an annualized basis and a dividend yield of 2.83%. The ex-dividend date was Wednesday, February 14th. Eli Lilly and’s dividend payout ratio is currently -1,124.94%.
In other news, major shareholder Lilly Endowment Inc sold 200,000 shares of the company’s stock in a transaction on Wednesday, December 13th. The shares were sold at an average price of $88.20, for a total value of $17,640,000.00. Following the sale, the insider now directly owns 123,084,104 shares of the company’s stock, valued at approximately $10,856,017,972.80. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Donald A. Zakrowski sold 860 shares of the company’s stock in a transaction on Thursday, March 1st. The shares were sold at an average price of $76.50, for a total transaction of $65,790.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 224,761 shares of company stock worth $19,708,235. Insiders own 0.20% of the company’s stock.
A number of equities analysts recently issued reports on the stock. Goldman Sachs Group cut shares of Eli Lilly and from a “buy” rating to a “neutral” rating and upped their price objective for the stock from $86.98 to $95.00 in a research report on Tuesday, January 16th. Jefferies Group set a $100.00 price objective on shares of Eli Lilly and and gave the stock a “buy” rating in a research report on Tuesday, January 16th. Credit Suisse Group reiterated a “hold” rating on shares of Eli Lilly and in a research report on Wednesday, December 13th. BMO Capital Markets set a $73.00 price objective on shares of Eli Lilly and and gave the stock a “sell” rating in a research report on Tuesday, December 12th. Finally, Argus upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and upped their price objective for the stock from $85.52 to $115.00 in a research report on Friday, January 5th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $93.47.
ILLEGAL ACTIVITY WARNING: This piece was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The original version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3253927/ironvine-capital-partners-llc-takes-position-in-eli-lilly-and-co-lly.html.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.